Back to News
Market Impact: 0.2
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Source: GlobeNewswire
Patents & Intellectual PropertyHealthcare & Biotech
NeuroThera filed U.S. patent applications covering proprietary combinations of its PEA technology with LSD, ketamine and ibogaine. The proposed therapeutic applications include depression, PTSD and substance-use disorders, potentially strengthening the company’s intellectual-property position in psychedelic-based mental-health treatments.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy
- J&J presents patient data on nipocalimab for Sjögren’s disease
- Rent-a-grandchild: Businesses offering companions to elderly grow in India
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?
- Equity Research Automation Statistics: A 2026 Evidence Check